Drugs Containing Excipient (Inactive Ingredient) PALMITOSTEARIC ACID

Generic drugs containing PALMITOSTEARIC ACID excipient

Company	Ingredient	NDC	Excipient
NCS HealthCare of KY LLC dba Vangard Labs	bupropion hydrochloride	0615-8581	PALMITOSTEARIC ACID
Rising Pharma Holdings Inc	dicyclomine hydrochloride	16571-259	PALMITOSTEARIC ACID
Camber Pharmaceuticals Inc	dicyclomine hydrochloride	31722-079	PALMITOSTEARIC ACID
A-S Medication Solutions	glipizide	50090-7402	PALMITOSTEARIC ACID
A-S Medication Solutions	glipizide	50090-7403	PALMITOSTEARIC ACID

Palmitostearic Acid: Market Dynamics and Financial Trajectory for a Key Pharmaceutical Excipient

Last updated: February 19, 2026

Palmitostearic acid, a saturated fatty acid with a 16-carbon chain, functions as a critical excipient in pharmaceutical formulations. Its primary roles include acting as a lubricant, binder, and emulsifier, contributing to tablet manufacturing efficiency, drug dissolution rates, and product stability. The global market for palmitostearic acid is driven by the expanding pharmaceutical industry, increasing demand for oral solid dosage forms, and advancements in drug delivery systems. Supply chain dynamics, raw material availability, and regulatory compliance are key factors influencing its market trajectory.

What is the Current Market Size and Projected Growth for Palmitostearic Acid?

The global market for palmitostearic acid in pharmaceutical applications is estimated at $250 million in 2023, with projections indicating a compound annual growth rate (CAGR) of 4.5% from 2024 to 2030. This growth is attributed to several factors. The increasing prevalence of chronic diseases worldwide necessitates a higher output of pharmaceutical products, predominantly oral solid dosage forms where palmitostearic acid is extensively used. For example, the global market for diabetes drugs, a significant segment of chronic disease treatment, is projected to reach $120 billion by 2028 [1], indirectly boosting demand for excipients like palmitostearic acid.

Furthermore, the expanding pharmaceutical contract manufacturing organization (CMO) sector contributes to market expansion. CMOs, which handle a substantial portion of drug production, require a consistent and reliable supply of high-quality excipients. The global pharmaceutical contract manufacturing market was valued at $140 billion in 2022 and is expected to grow at a CAGR of 6.2% through 2028 [2].

Emerging markets in Asia-Pacific and Latin America are also significant contributors to growth. Increased healthcare spending, rising disposable incomes, and improving pharmaceutical manufacturing infrastructure in these regions are driving demand for pharmaceutical excipients. China and India, in particular, represent key growth areas due to their large populations and expanding generic drug manufacturing capabilities.

What are the Primary Applications and Demand Drivers for Palmitostearic Acid in Pharmaceuticals?

Palmitostearic acid's utility stems from its physical and chemical properties, making it a versatile excipient in pharmaceutical manufacturing. Its primary applications include:

• Lubricant: In tablet manufacturing, palmitostearic acid reduces friction between the tablet blend and the die walls, preventing sticking and ensuring smooth ejection of tablets. This is crucial for high-speed tablet compression machines, increasing manufacturing throughput. A typical concentration range as a lubricant is 0.5% to 2% by weight of the tablet formulation.
• Binder: It can act as a binder, helping to agglomerate powder particles into granules. This improves the flowability and compressibility of the powder mixture, leading to more uniform tablet weight and hardness. Granulation is often employed for powders that exhibit poor flow properties, a common challenge in drug formulation.
• Emulsifier/Stabilizer: In semi-solid and liquid dosage forms, such as creams and ointments, palmitostearic acid functions as an emulsifier, stabilizing oil-in-water or water-in-oil emulsions. It helps to create a uniform and stable product, preventing phase separation and ensuring consistent drug delivery. It is also used in sustained-release formulations to control drug diffusion rates.

Demand for palmitostearic acid is directly linked to the production volume of various pharmaceutical dosage forms, including:

• Oral Solid Dosage Forms: Tablets and capsules represent the largest segment by volume. The convenience and patient compliance associated with these forms drive their widespread use. The global tablet market alone is projected to reach $110 billion by 2027 [3].
• Semi-Solid Formulations: Creams, ointments, and gels, particularly for dermatological and topical applications, utilize palmitostearic acid for emulsion stability.
• Specialty Drug Delivery Systems: Its role in controlled-release formulations, where it influences drug release kinetics, is an area of growing demand as pharmaceutical companies develop more sophisticated drug delivery technologies.

The increasing focus on patient convenience and adherence to medication regimens further underpins the demand for oral solid dosage forms, and consequently, for essential excipients like palmitostearic acid.

What are the Key Raw Materials and Supply Chain Considerations for Palmitostearic Acid?

Palmitostearic acid is primarily derived from palm oil and palm kernel oil. These are renewable agricultural commodities. The global production of palm oil is concentrated in Southeast Asia, with Indonesia and Malaysia accounting for over 85% of the world's supply [4].

The supply chain for palmitostearic acid involves several stages:

1. Agricultural Sourcing: Extraction of crude palm oil from oil palm plantations.
2. Refining and Fractionation: Crude palm oil undergoes refining to remove impurities, followed by fractionation to separate different fatty acids based on their melting points. Palmitostearic acid is typically obtained as a fraction from this process.
3. Chemical Processing: Further purification and sometimes esterification or hydrogenation steps may be employed to achieve pharmaceutical-grade specifications.
4. Distribution: Pharmaceutical-grade palmitostearic acid is then supplied to drug manufacturers globally.

Key supply chain considerations include:

• Volatility of Agricultural Commodity Prices: The price of palm oil can fluctuate significantly due to weather patterns, geopolitical events, and changes in global demand for edible oils. This volatility directly impacts the cost of palmitostearic acid. For instance, a 10% increase in palm oil prices can translate to a 3-5% increase in excipient costs.
• Sustainability and Ethical Sourcing: There is increasing scrutiny on the sustainability of palm oil production, with concerns regarding deforestation and biodiversity loss. Pharmaceutical companies are increasingly demanding excipients sourced from certified sustainable palm oil (CSPO) sources. The Roundtable on Sustainable Palm Oil (RSPO) certification is a key standard in this regard. Suppliers are investing in ensuring their supply chains meet these ethical and environmental standards.
• Geopolitical Risks: Concentration of production in a few countries, such as Indonesia and Malaysia, makes the supply chain vulnerable to geopolitical instability, trade disputes, or natural disasters.
• Regulatory Compliance: Pharmaceutical-grade palmitostearic acid must meet stringent purity and quality standards set by pharmacopoeias such as the United States Pharmacopeia (USP), European Pharmacopoeia (EP), and Japanese Pharmacopoeia (JP). Manufacturers must adhere to Good Manufacturing Practices (GMP) throughout the production process.

The dependence on palm oil can also lead to discussions about alternative sourcing, such as stearic acid derived from other vegetable oils or animal fats, though palm oil-based palmitostearic acid often offers a favorable cost-benefit profile for many applications.

What are the Key Manufacturers and Competitive Landscape of Palmitostearic Acid?

The market for pharmaceutical-grade palmitostearic acid is characterized by a mix of large, diversified chemical companies and specialized excipient manufacturers. Key players are focused on maintaining high-quality production standards, ensuring regulatory compliance, and managing their supply chains effectively.

Major manufacturers of palmitostearic acid include:

• Croda International Plc: A global leader in specialty chemicals, Croda offers a range of pharmaceutical excipients, including fatty acids derived from plant sources. They have a strong focus on sustainability and product quality.
• IOI Oleochemicals: A significant producer of oleochemicals, IOI Oleochemicals is a major supplier of palm oil derivatives, including palmitostearic acid, to the pharmaceutical industry.
• KLK Oleo: Part of Kuala Lumpur Kepong Berhad, KLK Oleo is another large integrated palm oil producer with a substantial oleochemical division supplying pharmaceutical-grade ingredients.
• VVF Limited: An Indian-based company that manufactures and supplies a broad spectrum of oleochemicals and personal care ingredients, including fatty acids for pharmaceutical use.
• Oxiteno S.A. Indústria e Comércio: A Brazilian multinational that produces a range of specialty chemicals, including fatty acids.

The competitive landscape is driven by:

• Product Quality and Purity: Pharmaceutical manufacturers prioritize excipients that meet rigorous pharmacopoeial standards to ensure drug safety and efficacy.
• Regulatory Support and Documentation: Manufacturers must provide comprehensive documentation, including Certificates of Analysis (CoA), Drug Master Files (DMFs), and support for regulatory submissions.
• Supply Chain Reliability and Security: Consistent availability and a secure supply chain are critical for uninterrupted drug production.
• Price Competitiveness: While quality is paramount, cost-effectiveness remains a significant factor, especially for high-volume generic drug manufacturers.
• Innovation in Excipient Functionality: Some manufacturers are exploring ways to enhance the functional properties of palmitostearic acid, such as improved compressibility or controlled-release capabilities, to meet evolving formulation needs.

The market is moderately consolidated, with a few dominant players holding significant market share. Strategic partnerships and acquisitions are common as companies aim to expand their product portfolios and global reach.

What are the Regulatory Frameworks and Quality Standards Governing Palmitostearic Acid?

The use of palmitostearic acid as a pharmaceutical excipient is strictly regulated by global health authorities to ensure patient safety and product quality. Key regulatory frameworks and quality standards include:

• Pharmacopoeial Standards:
  • United States Pharmacopeia (USP): Palmitostearic acid is listed, and its monograph specifies requirements for identification, purity, assay, and limits for impurities such as heavy metals and related fatty acids. For example, the USP monograph may define a range for the percentage of C16:0 fatty acid content.
  • European Pharmacopoeia (EP): Similar to the USP, the EP sets forth quality standards and testing methods for palmitostearic acid used in pharmaceutical preparations.
  • Japanese Pharmacopoeia (JP): The JP also provides specific monographs and quality requirements for pharmaceutical ingredients.
• Good Manufacturing Practices (GMP): Manufacturers of pharmaceutical excipients must comply with GMP regulations, which ensure that products are consistently produced and controlled according to quality standards appropriate for their intended use. This includes aspects of facility design, equipment, personnel training, process validation, and quality control.
• Food and Drug Administration (FDA) Regulations (USA): The FDA regulates drug products and their components. Excipients must be safe and suitable for their intended use. Manufacturers often file Drug Master Files (DMFs) with the FDA to provide detailed information about the manufacturing process, facilities, and quality control of their excipients.
• European Medicines Agency (EMA) Regulations (Europe): The EMA oversees the regulation of medicines in the European Union. Similar to the FDA, they require comprehensive data on excipients used in medicinal products.
• REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) in Europe: While primarily focused on chemical safety, REACH regulations can impact the production and use of excipients within the EU.
• ICH Guidelines: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) provides guidelines on quality, safety, and efficacy. ICH Q7, for example, provides guidance on GMP for Active Pharmaceutical Ingredients, which also has relevance for excipient manufacturing.

Key quality parameters typically monitored include:

• Purity: Minimum percentage of palmitostearic acid (C16:0) and limits for other fatty acids.
• Melting Point: A defined range, typically around 50-55°C, indicating purity.
• Acid Value: A measure of free fatty acids.
• Iodine Value: Indicating the degree of unsaturation; should be very low for saturated fatty acids.
• Heavy Metals: Limits for lead, arsenic, and other heavy metal contaminants.
• Microbial Limits: Absence of harmful microorganisms.

Compliance with these standards is non-negotiable and forms the basis of trust between excipient suppliers and pharmaceutical manufacturers. Deviations can lead to product recalls, regulatory sanctions, and significant financial losses.

What are the Future Trends and Innovations in Palmitostearic Acid Usage?

The pharmaceutical excipient market, including that for palmitostearic acid, is dynamic, driven by evolving drug development trends and manufacturing technologies. Future trends and innovations are likely to focus on enhanced functionality, sustainability, and personalized medicine applications.

Key future trends include:

• Enhanced Functional Properties: Research into modifying palmitostearic acid or using it in combination with other excipients to achieve specific functionalities, such as:
  • Improved Compressibility: Developing formulations that allow for higher tablet tensile strength with lower compression forces, leading to more efficient manufacturing and potentially smaller tablet sizes.
  • Controlled Release: Further utilization in matrix systems or as a coating material to precisely control the rate and duration of drug release, particularly for complex molecules or combination therapies. For example, using it in lipid-based drug delivery systems (LBDDS) to improve bioavailability of poorly soluble drugs.
  • Enhanced Solubility: Incorporating palmitostearic acid into amorphous solid dispersions or nano-suspensions to increase the solubility and absorption of poorly water-soluble active pharmaceutical ingredients (APIs).
• Sustainability and Traceability: With increasing global emphasis on environmental, social, and governance (ESG) factors, there will be a continued push for:
  • Certified Sustainable Palm Oil (CSPO): Greater demand for palmitostearic acid derived from RSPO-certified sources, ensuring responsible sourcing and minimal environmental impact.
  • Traceable Supply Chains: Technologies like blockchain may be employed to provide end-to-end traceability of raw materials, from plantation to finished excipient.
  • Alternative Feedstocks: While palm oil is dominant, ongoing research may explore cost-effective and sustainable alternatives for fatty acid production, though wide-scale adoption will depend on economic feasibility and regulatory acceptance.
• Personalized Medicine and Advanced Drug Delivery: As personalized medicine gains traction, there may be a need for excipients that can be tailored to specific patient populations or individual treatment needs. This could involve developing excipients with highly specific release profiles or that can be incorporated into novel dosage forms for targeted delivery.
• Continuous Manufacturing: The pharmaceutical industry's move towards continuous manufacturing processes, which offer potential benefits in efficiency, quality control, and reduced footprint, will require excipients that are compatible with these advanced production methods. Palmitostearic acid's properties as a lubricant and binder are well-suited for powder flow and granulation steps inherent in continuous processes.
• Biocompatibility and Safety: Ongoing scrutiny of all pharmaceutical ingredients will ensure continued focus on the biocompatibility and long-term safety profile of palmitostearic acid, particularly as it is used in a wider range of drug products and patient populations.

These trends suggest a sustained demand for palmitostearic acid, with opportunities for manufacturers to innovate and differentiate through enhanced product performance, robust sustainability practices, and a strong commitment to regulatory compliance.

Key Takeaways

The market for palmitostearic acid as a pharmaceutical excipient is projected to grow at a CAGR of 4.5% through 2030, driven by the expanding pharmaceutical industry and the increasing demand for oral solid dosage forms. Its versatility as a lubricant, binder, and emulsifier underpins its widespread use in tablet manufacturing and semi-solid formulations. Supply chain stability is contingent on palm oil production, making price volatility and sustainability concerns key factors. Major manufacturers focus on stringent quality control, regulatory compliance, and reliable sourcing to serve a global market. Future innovations are expected to enhance its functional properties, address sustainability demands, and support advancements in personalized medicine and continuous manufacturing.

Frequently Asked Questions

1. What is the primary risk associated with the supply chain for palmitostearic acid? The primary risk is the volatility of palm oil prices, which directly impacts the cost of palmitostearic acid. Geopolitical instability in major palm oil-producing regions and weather-related disruptions also pose significant supply chain risks.

2. How does palmitostearic acid contribute to tablet manufacturing efficiency? As a lubricant, palmitostearic acid reduces friction between the tablet blend and the die walls of tablet presses. This prevents sticking, allows for higher compression speeds, and ensures consistent ejection of tablets, thereby increasing manufacturing throughput and efficiency.

3. Are there any widely accepted alternatives to palm oil-derived palmitostearic acid in pharmaceuticals? While other fatty acids exist, such as stearic acid derived from tallow or other vegetable oils, palmitostearic acid derived from palm oil often presents a balance of functional performance and cost-effectiveness. The search for sustainable and cost-competitive alternatives is ongoing, but direct replacements with equivalent performance profiles are not always readily available for all applications.

4. What are the critical quality attributes for pharmaceutical-grade palmitostearic acid? Critical quality attributes include high purity (specific C16:0 content), low levels of other fatty acids, a defined melting point range, minimal impurities like heavy metals, and adherence to microbial limits as specified by pharmacopoeias such as USP, EP, and JP.

5. How is the demand for palmitostearic acid influenced by the growth of generic drugs? The growth of generic drugs, which often constitute a significant volume of oral solid dosage forms, directly increases the demand for excipients like palmitostearic acid. Generic manufacturers rely on cost-effective and reliable excipients to produce high-quality, affordable medications.

Citations

[1] Grand View Research. (2023). Diabetes drugs market size, share & trends analysis report by drug class (insulin, incretin mimetics, SGLT2 inhibitors), by diabetes type (type 1, type 2), by distribution channel (hospital pharmacy, retail pharmacy, online pharmacy), by region, and segment forecasts, 2023 - 2030.

[2] Mordor Intelligence. (2023). Pharmaceutical Contract Manufacturing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2024 - 2029).

[3] Global Market Insights. (2023). Tablet Market Analysis Report.

[4] U.S. Department of Agriculture. (2023). Oilseeds: World Markets and Trade.